MONMOUTH JUNCTION, NJ, May 2, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the company has been awarded a new preferred supplier for CytoSorb® with Asklepios Group (Asklepios), one of the largest private hospital operators in Germanyfollowing the majority acquisition of RHÖN‑KLINIKUM AG in 2020.

CytoSorbents has entered into a 3-year Preferred Supplier Agreement with Asklepios, making CytoSorb available without restrictions to all approximately 170 healthcare facilities in 14 states across Germany that Asklepios operates. This includes Asklepios Klinik St. Georg at Hamburg, Germanywho pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery, and is well known for his pioneering publication on the use of CytoSorb for this application during emergency cardiac surgery in patients with high risk of bleeding.

dr. Christian SteinerExecutive Vice President, Sales and Marketing of CytoSorbents, said, “We are delighted to announce this agreement with Asklepios, as we are now their preferred provider of hemoadsorption technology. With this new agreement, CytoSorbents now has preferred supplier agreements with the three largest chain hospitals in Germany, providing an opportunity to further grow our business. These private hospital chains are always on the lookout for value-added therapies that provide both clinical and economic benefits to ensure the highest quality medical care for their patients while supporting cost-effective operations. I am confident that CytoSorb helps these hospital chains achieve both of these goals.”

About Asklepios Group
Asklepios was established in 1985 and is today one of the leading private hospital operators in Germany. The business activities of Asklepios have always been aimed at providing patients with medicine of the future based on the highest quality standards. Asklepios aspires to shape the future of medicine. One of the keys also lies in digitization. Asklepios’ vision of a fully integrated digital health group is summed up in the term “Digital HealthyNear”. The Group currently has approximately 170 healthcare facilities across Germany represented in 14 German federal states functioning as a national network for the provision of holistic healthcare. These include acute care hospitals at all levels of care, teaching hospitals, specialist hospitals, prevention and monitoring centres, rehabilitation clinics and medical centres. In fiscal year 2021, more than 3.5 million patients were treated at Asklepios Group facilities. The company has more than 67,000 employees. For more information, visit www.asklepios.com.

About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in critical care and cardiac surgery using blood purification. Its lead product, CytoSorb®, is approved in the European Union with distribution in over 70 countries worldwide as an extracorporeal cytokine adsorber designed to reduce “cytokine storm” or “cytokine release syndrome”. cytokines” seen in common serious illnesses that can result in massive inflammation, organ failure, and patient death. These are conditions where the risk of death can be extremely high, but there are few or no effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to postoperative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been used from the 31st of December, 2021. CytoSorb was originally introduced in the European Union under CE marking as the first cytokine adsorber. Additional CE mark extensions have been received for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for both ticagrelor and rivaroxaban during cardiothoracic surgery . CytoSorb has also received emergency use authorization from the US FDA for use in critically ill adult COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb™-ATR antithrombotic elimination system, which is based on the same polymer technology as CytoSorb, has also received FDA Breakthrough Designation for the elimination of ticagrelor, as well as FDA Breakthrough Designation for Elimination of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The company has initiated two pivotal FDA-approved trials designed to support the marketing approval of DrugSorb-ATR in the United States. The first is the center for 120 patients, 30 TO START UP (Ssafe and Jtimely Aantithrombotic Rmoving house-Jicagrelor) randomized controlled trial evaluating the ability of intraoperative use of DrugSorb-ATR to reduce the risk of perioperative bleeding in patients on ticagrelor undergoing cardiothoracic surgery. The second is the center for 120 patients, 30 STAR‑D (Ssafe and Jtimely Aantithrombotic Rmoving house-Ddirect oral anticoagulants) randomized controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce the risk of perioperative bleeding in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.

CytoSorbents purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received more than $39.5 million in grants, contracts, and other non-dilutive funding from DARPA, the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH ), National Heart, Lung, and Blood Institute (NHLBI), U.S. Army, U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others . The company has numerous marketed products and products in development based on this unique blood purification technology protected by numerous issued U.S. and international patents and trademarks, and several pending patent applications, including ECOS-300CY®, CytoSorb -XL™, HemoDefend-RBC™ , HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-looking statements

This press release contains forward-looking statements intended to qualify for the safe harbor rule established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlook for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and assertions and are not historical facts and are generally identified by the use of terms such as “may”, “should”, “could”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “continue” and similar words, although certain forward-looking statements are expressed differently. You should be aware that the forward-looking statements contained in this press release represent the current judgment and expectations of management, but our actual results, events and performance could differ materially from those contained in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our quarterly reports on Form 10-Q, as well as in press releases and other shareholder communications that we issue from time to time that attempt to inform interested parties of the risks. and factors that may affect our business. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.

Please click to follow us on Facebook and Twitter

Contact with Investor Relations:
Terri Anne Powers
Vice President, Investor Relations
and corporate communications
(732) 482-9984
[email protected]

US Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
[email protected]

SOURCE CytoSorbents Corporation